Back to Sites

Baylor College of Medicine/ Texas Children's Hospital NICHD CRS

Site Number

5128

Address

Baylor College of Medicine/Texas Children's Hospital
1102 Bates Street
Suite FC 630
Houston, TX 77030-2399
United States of America

IMPAACT Members at this Site

Theresa Aldape CAB Liaison

Susan Gillespie M.D. Co-Investigator

Chivon McMullen-Jackson CRS Coordinator

Mary Paul CRS Leader

Stuart Abramson CRS Staff

Renee Ali CRS Staff

Cassandra Armstrong CRS Staff

Carol Baker CRS Staff

Margaret 'Missy' Bauman CRS Staff

Marsella Blaine-Casey CRS Staff

Shelley Buschur CRS Staff

Janet Ailene Englund CRS Staff

Hunter H. Hammill CRS Staff

I. Celine Hanson CRS Staff

Kimberly Jenkins CRS Staff

Valencia Johnson CRS Staff

Sharon Jones CRS Staff

Aaron Loeb CRS Staff

Faith Minglana CRS Staff

Lisa Moreau CRS Staff

Thuy Nguyen CRS Staff

Christine M. Owen CRS Staff

Mary Paul CRS Staff

Terry Raburn CRS Staff

Amber Sahmel CRS Staff

Shalonda Smith CRS Staff

Stephen Spector CTU Principal Investigator

Dara Potter DAIDS PO

Joseph Carnot Data Manager

Howard Rosenblatt Flow Cytometry Supervisor

Betty Brown Immunology Chief Technician

Desiree Evans Investigator

Elizabeth Lowenthal Investigator

Heidi Schwarzwald Investigator

Erin Bailey Laboratory Technician

Tara McCartney Pharmacist

Courtney Fletcher Pharmacologist

Uche Anigbogu Research Assistant

Christine Cambrice Research Nurse

Norma Cooper Research Nurse

Michelle Delrey Research Nurse

Larraine Lyter-Reed Research Nurse

Kathy Pitts Research Nurse

F. Blaine Hollinger Site Virologist

Nancy Calles Study Coordinator

Ruth Eser-Jose Study Coordinator

Eddie Siedel Virology Chief Technician

Studies at this Site

P1026S: PK in Pregnancy

DAIDS Number

Therapeutics

Research Area

Treatment

Study Status

Closed to Follow Up

P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

38530

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

DAIDS Number

38637

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

DAIDS Number

38693

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States

DAIDS Number

38746

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2017: MOCHA

DAIDS Number

30070

Research Area

Therapeutics

Study Status

Closed to Accrual

IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1

DAIDS Number

38962

Research Area

Therapeutics

Study Status

Pending

IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in People with Hepatitis C with and without HIV

DAIDS Number

39052

Research Area

Therapeutics

Study Status

In Development